CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children--Adviso- ry Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59: 258-61.CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use...
Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–117. doi: 10.15585/mmwr.mm7104a1. (Open in a new window)PubMed (Open in a...
The objective of this study was to estimate the annual population-level impact of PCV13 NIPs on vaccine-type and non-vaccine type (NVT) IPD incidence among children and adults using national surveillance data of countries that switched from PCV7 to PCV13 in their NIP. A 20-valent vaccine (...
The evolution of PCV2 is affected by both natural and vaccine-induced immune responses, which enhances the genetic variability, especially in the most immunogenic Cap region. Intra-host variability has been also demonstrated in infected animals where long-lasting infections can take place. However, ...
Our data also support flexibility in timing of first dose and opportunistic vaccine recommendations. Importantly we have demonstrated the safety and superior immunogenicity of combining PCV13 and PHiD-CV10 in a primary course schedule that commences at one month of age, with no immunological ...
Use of 15- valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among US adults: updated recommendations of the advisory committee on immunization practice (ACIP)–United States, 2022 Morb Mortal Wkly Rep, 71 (4) (2022), pp. 109-117 CrossrefView in ScopusGoogle Scho...
ACIP Recommendations for PCV13 and PPSV23 Use NM Bennett,CG Whitney,M Moore,... - 《Jama Journal of the American Medical Association》 被引量: 0发表: 2013年 Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising ...
The vaccine is used for preventing invasive pneumococcal disease caused by the 13 pneumococcal serotypes covered by the vaccine. The formulation of the vaccine, its immunogenicity profile, and safety profile are discussed. The article also provides an overview of indications and guidance for use, ...
Hare, et al. Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group Vaccine., 32 (2013), pp. 165-179 View PDFView articleView in ScopusGoogle Scholar...
and its recommendations for use among children. The U.S. Food and Drug Administration (FDA) gave license to Wyeth Pharmaceuticals Inc. for the 13-valent pneumococcal conjugate vaccine (PCV13). The Advisory Committee on Immunization Practices (ACIP) suggested that all children between 2-59 months...